Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - November 2013

 

Expertise in Neuropharmacology

  www.neuroact.com

 

    

 

   

Autumn News

Karolinska Institute lecture

Dr. Adrian Newman-Tancredi PhD, Dsc gave an invited lecture at the Karolinska Institute in Stockholm, Sweden on 25 September 2103. His presentation reviewed advances in the pharmacology of antipsychotics, with particular reference to serotonergic mechanisms.

ECNP Session on BPSD

Dr Newman-Tancredi and Prof. Przemyslaw Bienkowski MD led a 'Brainstorming Session' at the European College of Neuropsychopharmacology (ECNP) meeting ion Barcelona, Spain, on 8 October 2013. Discussion centred on the growing need for improved drugs to treat Behavioral and Psychological Symptoms of Dementia (BPSD). 

Parkinson's Disease Therapeutic Conference

Dr Newman-Tancredi presented at the Parkinson's Disease Therapeutics conference at the New York Academy of Science in New York City on 24 October 2013. The conference was sponsored by the Michael J. Fox Foundation and focussed on cutting edge advances in treatment of PD. 

 


 

 

 

 

 

 

 

 

 

 

Neurolixis Update

Adrian Newman-Tancredi is co-founder and Chief Scientific Officer of Neurolixis Inc., a CNS-focused bioscience company. 

Neurolixis has in-licensed two clinical-phase drugs for treatment of neurological disorders. The drugs are targeted to treatment of dyskinesia in Parkinson's disease and respiratory deficits in Rett syndrome, a genetically encoded neurological disorder. The FDA has awarded Neurolixis Orphan Drug status for the latter program.

Neurolixis is actively seeking collaborations to develop these drugs.
For further information, Contact.

 

New grant awarded by Fox Foundation

Adrian Newman-Tancredi is Principal Investigator of a new grant award from the Michael J Fox Foundation. The grant will support investigation of the effects serotonin 5-HT1A agonists in models of Parkinson's Disease. Specifically, the project will determine the effects of the drugs in measures of neurochemistry in collaboration with Dr. Andrew McCreary of BrainsOnline (Groningen, Netherlands). 

For further information click here.

 

 
Scientific Communication

Forthcoming Society for Neuroscience poster presentations in San Diego (CA):

(click on links to view Abstracts)

Activity of serotonin 5-HT1A receptor biased agonists in rat models of Parkinson’s disease: Potential for improved therapeutic management.

H. Iderberg, M.A. Cenci, M.A. Varney, A. Newman-Tancredi. Sat, Nov 9, 1:00 - 2:00 PM; 63.13/FF1

Activity of serotonin 5-HT1A receptor biased agonists in rat models of depression and syndrome: Superior profile of the post-synaptic preferential agonist, F15599.

M.J. O'Callaghan, W.C. Li, R.A. McArthur, M. Varney, A. Newman-Tancredi. Sun, Nov 10, 3:00 - 4:00 PM; 258.11/NN1

Divergent effects of the novel, “biased”, 5-HT1A receptor agonists F15599 and F13714 in a novel cognition task: object pattern separation.

R. Schreiber, N. Van Goenthem, A. Newman-Tancredi, M. Varney, J. Prickaerts. Wed, Nov 13, 2:00 - 3:00 PM; 865.18/KKK61

 

 

 

NeuroAct Communication advises lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs. 

 NeuroAct Communication is an independent consulting service founded by
Adrian Newman-Tancredi PhD DSc, an experienced pharmaceutical industry professional.

Find out more about Adrian in his Executive Profile